Bayer (FRA:BAYN) has been assigned a €77.00 ($90.59) price target by analysts at JPMorgan Chase & Co. in a research report issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 76.52% from the company’s current price.
A number of other equities analysts have also recently issued reports on the stock. Independent Research set a €48.00 ($56.47) target price on shares of Bayer and gave the stock a “neutral” rating in a report on Friday, October 2nd. Berenberg Bank set a €76.00 ($89.41) target price on shares of Bayer and gave the stock a “buy” rating in a report on Tuesday, August 11th. Nord/LB set a €60.00 ($70.59) price target on Bayer and gave the company a “buy” rating in a report on Tuesday, October 6th. Morgan Stanley set a €68.00 ($80.00) price target on Bayer and gave the company a “buy” rating in a report on Wednesday. Finally, Barclays set a €50.00 ($58.82) price objective on shares of Bayer and gave the company a “neutral” rating in a research note on Tuesday, October 13th. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of €74.81 ($88.01).
Shares of BAYN stock opened at €43.62 ($51.32) on Wednesday. Bayer has a one year low of €91.58 ($107.74) and a one year high of €123.82 ($145.67). The company’s 50-day simple moving average is €51.68 and its 200-day simple moving average is €58.31.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: G-20
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.